On June 26, 2025 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred to as "natural hotspots," reported it will present preclinical data from the Company’s CARD11-BCL10-MALT1 (CBM) program in two poster presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Gastrointestinal Cancers Congress 2025, taking place July 2-5, 2025, in Barcelona, Spain (Press release, HotSpot Therapeutics, JUN 26, 2025, View Source [SID1234654145]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: Synthetic lethality of CBM signalosome inhibition for KRAS-Mutant Colorectal Cancers
Poster Number: 124P
Session: Poster Display Session 2
Session Date and Time: Fri., Jul. 4, 5:30-6:30 CEST
Location: Foyer, International Barcelona Convention Center, Barcelona, Spain

Title: Novel CBM signalosome inhibitor revealed the essentiality of CBM signalosome for KRAS mutant colorectal cancer
Poster Number: 125P
Session: Poster Display Session 2
Session Date and Time: Fri., Jul. 4, 5:30-6:30 CEST
Location: Foyer, International Barcelona Convention Center, Barcelona, Spain